专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明专利

AU2015219161A1 Biomarker directed multi-target immunotherapy 未知
公开(公告)号：AU2015219161A1
公开(公告)日：2016-09-29
申请号：AU2015219161
申请日：2015-02-18
申请人： ADVAXIS INC
发明人： PETIT ROBERT
IPC分类号： A61K39/00
摘要： This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted Listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant Listeria strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said Listeria comprises a ' different biomarker, thereby treating said disease in said subject.

62. 发明专利

AU2013232291B8 Suppressor cell function inhibition following listeria vaccine treatment 未知
公开(公告)号：AU2013232291B8
公开(公告)日：2016-07-21
申请号：AU2013232291
申请日：2013-03-12
申请人： ADVAXIS INC
发明人： SINGH RESHMA , WALLECHA ANU
IPC分类号： A61K39/00 , A61K39/02
摘要： This invention provides methods and compositions for using a live attenuated

63. 发明专利

AU2013232291B2 Suppressor cell function inhibition following 未知
公开(公告)号：AU2013232291B2
公开(公告)日：2016-06-30
申请号：AU2013232291
申请日：2013-03-12
申请人： ADVAXIS INC
发明人： SINGH RESHMA , WALLECHA ANU
IPC分类号： A61K39/00 , A61K39/02
摘要： This invention provides methods and compositions for using a live attenuated

64. 发明专利

HK1207315A1 DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS 未知
公开(公告)号：HK1207315A1
公开(公告)日：2016-01-29
申请号：HK15108046
申请日：2015-08-19
申请人： ADVAXIS INC
发明人： MACIAG PAULO , WALLECHA ANU , SHAHABI VAFA
IPC分类号： A61K20060101 , A61K39/00 , A61P20060101
摘要： A recombinant Listeria strain expressing a fusion polypeptide, wherein the fusion polypeptide comprises a heterologous antigen fused to an N-terminal LLO, wherein the recombinant Listeria is an attenuated Listeria which comprises a mutation in the dal/dat genes, a metabolic enzyme that complements the dal/dat mutation, and a mutation or deletion of the endogenous actA gene, and medical uses thereof. The heterologous antigen may be Prostate Specific Antigen (PSA).

65. 发明专利

HUE024509T2 KLK3, PSCA vagy FOLH1 antigénnel összefüggõ készítmények és eljárások 未知
公开(公告)号：HUE024509T2
公开(公告)日：2016-01-28
申请号：HUE08754370
申请日：2008-05-12
申请人： UNIV PENNSYLVANIA , ADVAXIS INC
发明人： PATERSON YVONNE , ROTHMAN JOHN , SHAHABI VAFA
IPC分类号： A61K39/00 , A61K39/02 , A61P35/00 , C07K14/47 , C07K19/00

66. 发明专利

MA40344A COMBINAISON D'UN ANTAGONISTE DE PD-1 ET D'UN VACCIN À BASE DE LISTERIA POUR LE TRAITEMENT DU CANCER 未知
公开(公告)号：MA40344A
公开(公告)日：2016-01-21
申请号：MA40344
申请日：2015-07-17
申请人： ADVAXIS INC , MERCK SHARPE AND DOHME CORP
发明人： MAURO DAVID J , PERINI RODOLFO F , PETIT ROBERT
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
摘要： La présente invention concerne des polythérapies comprenant un antagoniste du récepteur de mort programmée 1 (pd -1) et une souche de listeria qui exprime un antigène spécifique des tissus de la prostate (psa), et l'utilisation de polythérapies pour le traitement du cancer de la prostate.

67. 发明专利

CA2955612A1 COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA-BASED VACCINE FOR TREATING PROSTATE CANCER 未知
公开(公告)号：CA2955612A1
公开(公告)日：2016-01-21
申请号：CA2955612
申请日：2015-07-17
申请人： ADVAXIS INC , MERCK SHARPE AND DOHME CORP
发明人： PETIT ROBERT , MAURO DAVID J , PERINI RODOLFO F
IPC分类号： A61K39/02 , A61K35/74 , A61K39/12 , A61P35/00
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.

68. 发明专利

HK1205944A1 SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING LISTERIA VACCINE TREATMENT 未知
公开(公告)号：HK1205944A1
公开(公告)日：2015-12-31
申请号：HK15106569
申请日：2015-07-09
申请人： ADVAXIS INC
发明人： SINGH RESHMA R , WALLECHA ANU A
IPC分类号： A61K20060101
摘要： This invention provides methods and compositions for using a live attenuated Listeria for inhibiting cell-mediated suppression of anti-disease infiltrating T lymphocytes in a subject having the disease.

69. 发明申请

WO2019157098A1 COMPOSITIONS COMPRISING A RECOMBINANT LISTERIA STRAIN AND AN ANTI-CCR8 ANTIBODY AND METHODS OF USE 审中-公开
公开(公告)号：WO2019157098A1
公开(公告)日：2019-08-15
申请号：PCT/US2019/016914
申请日：2019-02-06
申请人： ADVAXIS, INC.
发明人： VILLARREAL, Daniel
IPC分类号： A61K39/00 , A61K39/245 , A61K39/02 , A61K39/395 , A61P35/00
摘要： The subject matter described herein is directed to immunogenic compositions comprising (i) a recombinant Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide, wherein the fusion polypeptide comprises a PEST-containing peptide fused to an antigenic peptide and (ii) an anti-CCR8 antibody or a fragment thereof, and methods of treatment using the compositions. Also provided herein are recombinant fusion polypeptides comprising an antigenic peptideje.g., fused to a PEST-containing peptide). Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

70. 发明申请

WO2019006401A2 LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETEROCLITIC WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2019006401A2
公开(公告)日：2019-01-03
申请号：PCT/US2018/040457
申请日：2018-06-29
申请人： ADVAXIS, INC. , SELLAS LIFE SCIENCES GROUP LTD.
发明人： PRINCIOTTA, Michael , PETIT, Robert , GUTIERREZ, Andres A.
IPC分类号： C12N15/74 , C07K14/47 , C07K14/195 , A61K39/00 , A61K39/39 , A61P35/00
CPC分类号： A61P35/00 , A61K39/00 , A61K39/001153 , A61K39/02 , A61K39/39 , A61K2039/55516 , C07K14/4748 , C07K2319/00 , C07K2319/40 , C07K2319/95 , C12N15/62
摘要： Provided herein are recombinant fusion polypeptides comprising one or more antigenic Wilms tumor protein (WT1) peptides, wherein at least one of the antigenic WT1 peptides is a heteroclitic mutant WT1 peptide (e.g., fused to a PEST-containing peptide). Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-WT1 immune response in a subject, methods of inducing an anti-WT1-expressing-tumor or anti-WT1-expressing-cancer immune response in a subject, methods of treating a WT1-expressing or WT1-associated tumor or cancer in a subject, methods of preventing a WT1-expressing or WT1-associated tumor or cancer in a subject, and methods of protecting a subject against a WT1-expressing or WT1-associated tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式